NCT00541307View on ClinicalTrials.gov

GORE VIABAHN Endoprosthesis With Heparin Bioactive Surface in the Treatment of SFA Obstructive Disease (VIPER)

NACompletedINTERVENTIONAL
Enrollment

119

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

June 30, 2011

Study Completion Date

June 30, 2011

Conditions
Peripheral Vascular Diseases
Interventions
DEVICE

Treatment with the GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface

Endovascular treatment of the study lesion with the GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface

Trial Locations (5)

53233

St. Luke's Medical Center, Milwaukee

60616

Mercy Hospital and Medical Center, Chicago

65201

Columbia Surgical Associates, Columbia

75226

Baylor University Medical Center, Dallas

92056

Tri-City Medical Center, Oceanside

All Listed Sponsors
lead

W.L.Gore & Associates

INDUSTRY

NCT00541307 - GORE VIABAHN Endoprosthesis With Heparin Bioactive Surface in the Treatment of SFA Obstructive Disease (VIPER) | Biotech Hunter | Biotech Hunter